Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 13/20 | 0.58 |
| ▸ | AXL | P30530 | 12/20 | 0.58 |
| ▸ | BMPR1B | O00238 | 4/20 | 0.52 |
| ▸ | BMPR1A | P36894 | 4/20 | 0.52 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.52 |
| ▸ | ACVRL1 | P37023 | 4/20 | 0.52 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24838113 | 1.00 | MERTK (0.58) | MERTKAXLBMPR1BBMPR1ATGFBR1 | |
| SCHEMBL21779434 | 0.94 | AXL (0.60) | MERTKAXLBMPR1BBMPR1ATGFBR1 | |
| SCHEMBL18616317 | 0.93 | ACVR1 (0.56) | MERTKAXLBMPR1BBMPR1ATGFBR1 | |
| SCHEMBL18616322 | 0.91 | AXL (0.55) | MERTKAXLBMPR1BBMPR1ATGFBR1 | |
| SCHEMBL18615840 | 0.89 | MERTK (0.58) | MERTKAXLBMPR1BBMPR1ATGFBR1 | |
| SCHEMBL18617176 | 0.87 | MERTK (0.57) | MERTKAXLBMPR1BBMPR1ATGFBR1 | |
| SCHEMBL21779421 | 0.85 | AXL (0.61) | MERTKAXLBMPR1BBMPR1ATGFBR1 | |
| SCHEMBL18617188 | 0.85 | AXL (0.61) | MERTKAXLBMPR1BBMPR1ATGFBR1 | |
| SCHEMBL18616320 | 0.85 | AXL (0.60) | MERTKAXLBMPR1BBMPR1ATGFBR1 | |
| SCHEMBL20935467 | 0.83 | ACVR1 (0.50) | MERTKAXLBMPR1BBMPR1ATGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2023-01-05 | — | — | US | disclosed |
| EP-3344613-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2020-03-04 | — | — | EP | disclosed |
| WO-2017039331-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | MERTK 1/4885AXL 30/4885BMPR1B 2861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.